Quick Summary

Andrographis paniculata is a traditional herbal medicine historically used for infectious diseases, immune disorders, and liver injury. Its main active compound, andrographolide, and related derivatives have been studied for antibacterial, anti-inflammatory, immunomodulatory, antiviral, and potential anticancer effects. Clinical research primarily focuses on respiratory infections, including mild-to-moderate COVID-19 and upper respiratory tract infections, with some studies suggesting possible symptom improvement. Herbal preparations are generally considered safe, whereas andrographolide derivative injections carry a risk of adverse reactions, including rare but severe anaphylaxis.

What is it

Andrographis paniculata is a plant native to South Asian countries, commonly known as “King of Bitters.” It is used in traditional medicine systems such as Ayurveda and Traditional Chinese Medicine. The plant’s leaves and extracts contain bioactive compounds thought to contribute to its broad pharmacological properties.

Traditional Uses

  • Treatment of infectious diseases
  • Support for immune system disorders
  • Management of liver injury and related conditions
  • Relief from symptoms of respiratory tract infections
  • Anti-inflammatory applications

Active Compounds

The primary active compound is andrographolide, a diterpenoid lactone, along with its derivatives. These compounds are believed to underlie the herb’s pharmacological activities, including antimicrobial, anti-inflammatory, immunomodulatory, antiviral, and potential anticancer effects.

Potential Benefits with Evidence Levels

  • Mild-to-moderate COVID-19: Moderate-quality evidence from six randomized controlled trials with 660 adults found no significant improvement in fever or cough resolution compared to antivirals or supportive care, though some studies indicated trends toward symptom improvement and reduced inflammation.
    References: PMID 40822451, PMID 41908819, PMID 37765004
  • Acute respiratory tract infections (general): Systematic reviews including randomized controlled trials report that evidence for other phytopharmaceuticals is stronger; conclusive clinical benefits of Andrographis in children remain lacking.
    Reference: PMID 40376625
  • Acute lower respiratory tract infections and common cold: Kan Jang®, a fixed combination containing Andrographis, showed reduced COVID-19 severity, shorter recovery time, and symptom reduction in mild cases.
    Reference: PMID 37765004
  • Acute liver injury: Preclinical studies in vitro and in rat models suggest andrographolide may alleviate liver injury by inhibiting the NLRP3/Caspase-1/GSDMD-mediated pyroptosis pathway.
    Reference: PMID 41463396
  • Chronic obstructive pulmonary disease (COPD) related inflammation: In vitro, in silico, and animal studies indicate that Andrographis extracts may inhibit inflammatory cytokines such as TNF-α, IL-1β, and IL-6.
    Reference: PMID 40699661
  • Acute upper respiratory infections in children: Some traditional Chinese medicine injections containing andrographolide formulas show symptom relief and safety; direct evidence for pure Andrographis paniculata is limited.
    Reference: PMID 38915872
  • Gastrointestinal infections and inflammation: Andrographolide and derivatives may modulate inflammatory responses based on preclinical and traditional use data; robust clinical evidence is insufficient.
    Reference: PMID 40741601
  • Cancer (in vitro gastric cancer cell lines): In vitro studies suggest andrographolide can inhibit proliferation and induce apoptosis in gastric cancer cells; clinical evidence is lacking.
    Reference: PMID 39583105

Side Effects

  • Gastrointestinal symptoms (e.g., mild to moderate discomfort)
  • Skin and subcutaneous tissue disorders
  • Rare but potentially life-threatening anaphylaxis, especially with andrographolide derivative injections
  • Transient mild to moderate liver enzyme elevations
  • No severe hepatotoxicity or renal toxicity observed in controlled short-term studies

Drug Interactions

There is insufficient robust clinical data on specific drug interactions involving Andrographis paniculata or andrographolide derivatives. Caution is advised due to potential effects on immune and inflammatory pathways. Limited data exist regarding interactions with conventional medications; further research is needed.

Who Should Avoid It

  • Individuals with a history of hypersensitivity or allergic reactions to andrographolide derivative injections should avoid these formulations.
  • Those with known allergy to plant components or previous anaphylaxis should use caution or avoid herbal preparations.
  • Pregnant or breastfeeding women should avoid use due to lack of safety data.

Evidence Limitations

  • Most clinical evidence pertains to mild respiratory infections and specific compound formulations rather than isolated Andrographis extracts or pure andrographolide.
  • High variability and some risk of bias exist in randomized trials, especially relating to COVID-19 symptomatic treatment.
  • Lack of large, high-quality clinical trials using standardized extracts and dosages limits generalizability.
  • Many pharmacological claims derive primarily from in vitro and animal studies, limiting direct clinical relevance.
  • Safety data are mostly from short-term use; long-term safety remains unclear.
  • Limited information is available on pharmacokinetics and dose-response in humans.

References

Last Reviewed

2026

Disclaimer: This information is intended for educational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your healthcare provider with any questions regarding a medical condition or before starting any new herbal supplements.